Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Larkin

Showing results (361-370 of 398) with videos related to

Pageof 40
Sort By:
Genome|April 1, 1995
The use of cell culture for subchromosomal introgressions of barley yellow dwarf virus resistance from Thinopyrum intermedium to wheatP M Banks, P J Larkin, H S Bariana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2020
Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase III IMspire170 studyH Gogas, B Dréno, J Larkin, et al.
Palliative Medicine|April 21, 2026
Exploring engagement with a web-based self-directed psychoeducational program for advanced cancer patients and their caregivers (iFOCUS): A sub study analysis of the DIAdIC trialUlrik Sørensen Schmidt, Romy Van Rickstal, Vincent Van Goethem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)T Powles, J Brown, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
Magnetic Resonance in Medicine|September 22, 2015
(13) C magnetic resonance spectroscopy measurements with hyperpolarized [1-(13) C] pyruvate can be used to detect the expression of transgenic pyruvate decarboxylase activity in vivoPiotr Dzien, Sui-Seng Tee, Mikko I Kettunen, et al.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Cardiovascular Research|August 7, 2019
Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statementPiotr Z Sobanski, Bernd Alt-Epping, David C Currow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.
ESMO Open|September 3, 2021
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]T K Choueiri, J Larkin, S Pal, et al.
Pageof 40

Showing results (361-370 of 398) with videos related to

Sort By:
Pageof 40
Genome|April 1, 1995
The use of cell culture for subchromosomal introgressions of barley yellow dwarf virus resistance from Thinopyrum intermedium to wheatP M Banks, P J Larkin, H S Bariana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2020
Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase III IMspire170 studyH Gogas, B Dréno, J Larkin, et al.
Palliative Medicine|April 21, 2026
Exploring engagement with a web-based self-directed psychoeducational program for advanced cancer patients and their caregivers (iFOCUS): A sub study analysis of the DIAdIC trialUlrik Sørensen Schmidt, Romy Van Rickstal, Vincent Van Goethem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)T Powles, J Brown, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
Magnetic Resonance in Medicine|September 22, 2015
(13) C magnetic resonance spectroscopy measurements with hyperpolarized [1-(13) C] pyruvate can be used to detect the expression of transgenic pyruvate decarboxylase activity in vivoPiotr Dzien, Sui-Seng Tee, Mikko I Kettunen, et al.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Cardiovascular Research|August 7, 2019
Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statementPiotr Z Sobanski, Bernd Alt-Epping, David C Currow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.
ESMO Open|September 3, 2021
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]T K Choueiri, J Larkin, S Pal, et al.
Pageof 40